“What is drug repurposing and why is it relevant?”

Hans Platteeuw will first give a general introduction into drug repurposing and talk about the pros and cons compared to developing a new chemical entity as drug. Further, based on two use-cases, we will learn about opportunities but also challenges for repurposing and possible solutions.

Platteeuw is a chemist by training. He has a long-standing experience in product development in both the innovator, generics and value-added medicines industry. He is a founder and Chief Scientific Officer of Galenicap, a company fully dedicated to the development of New Therapeutic Entities. Galenicap acts as an incubator that starts from an academic concept to address a clinical need via existing medications, then transforms the concept into an unique pharmaceutical product with clinical proven endpoints of efficacy and safety and that verifies that all requirements are fulfilled to make the product ready to be available for patients globally including regulatory, intellectual property and financial considerations.

Register here!